The Latest News from Vascular Therapies
Vascular Therapies Announces Completion of Enrollment in the ACCESS Study, a U.S. Phase III Clinical Trial
CRESSKILL, NJ (Aug. 19, 2019)–Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced completion of enrollment in its US Phase III prospective randomized, multicenter, clinical study (ACCESS Trial).
Vascular Therapies Appoints John McDermott as Chief Executive Officer
CRESSKILL, NJ (January 15, 2019) –Vascular Therapies, a biotechnology company focused on improving outcomes for patients with advanced kidney disease today announced the appointment of John McDermott as the Company’s Chief Executive Officer.
Vascular Therapies Announces Preliminary Results from its Phase 3 AV Fistula Study
CRESSKILL, NJ (Nov. 9, 2017) – An innovative, investigational treatment approach is showing the potential to address an important, unresolved problem encountered by patients with kidney failure on dialysis.